FIG 3.
Kaplan-Meier estimates of PFS per BICR. (A) Patients with LAG-3 expression ≥1%; (B) patients with LAG-3 expression <1%; and (C) all randomly assigned patients. Symbols represent censored observations. BICR, blinded independent central review; chemo, chemotherapy; HR, hazard ratio; LAG-3, lymphocyte-activation gene 3; NIVO, nivolumab; PFS, progression-free survival; RELA, relatlimab.